Comparative Pharmacology
Head-to-head clinical analysis: ALDACTONE versus MIDAMOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDACTONE versus MIDAMOR.
ALDACTONE vs MIDAMOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive aldosterone receptor antagonist; increases sodium and water excretion, decreases potassium excretion at distal convoluted tubule.
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct, reducing sodium reabsorption and potassium excretion.
Initial: 50-100 mg orally once daily; may increase to 100-400 mg/day in divided doses (once to twice daily).
5 mg orally once daily, increased to 10 mg if needed; maximum 20 mg/day.
None Documented
None Documented
Spironolactone: 1.4-2.0 hours; Active metabolites (canrenone): 16.5-21.5 hours, clinically relevant for dosing interval
Terminal half-life 6-9 hours; prolonged in renal impairment (up to 20 hours) and in heart failure
Renal: 50-60% as metabolites (canrenone, other sulfur-containing metabolites), minor as unchanged drug; Biliary/Fecal: ~30-40%
Renal: 80-90% as unchanged drug; biliary/fecal: <5%
Category C
Category C
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic